Opinion: Saving lives should be good business. Why doesn’t that apply to finding new antibiotics?

I have spent my career as a biomedical entrepreneur working to develop products that have the potential to save lives while also generating returns for shareholders. Two years ago, I co-founded a new company, Octagon Therapeutics, focused on a critical unmet medical need and a growing market opportunity: more effective antibiotics. It turned out to be a disaster.

We invested significant resources into developing a promising treatment for infections caused by drug-resistant bacteria. These “superbugs,” which do not respond to most existing antibiotics, are responsible for nearly . If current trends continue, drug-resistant bacteria will be by 2050.

Stai leggendo un'anteprima, registrati per continuare a leggere.

Altro da STAT

STAT1 min lettiBiology
STAT+: Pharmalittle: Pfizer-BioNTech Vaccine Seems To Work Against Covid-19 Mutation; Sarepta Gene Therapy Shows Mixed Results
United Kingdom regulators cleared the Moderna Covid-19 vaccine, adding a third shot for emergency use against the pandemic as infections surge there.
STAT1 min lettiMedical
STAT+: Pharmalittle: Pfizer And BioNTech Say Vaccine Is Effective Against Covid-19 Variant; U.S. To Join COVAX Initiative
The Pfizer-BioNTech Covid-19 vaccine appears to work just as well against a fast-spreading variant first identified in the U.K. as it does against earlier forms of the coronavirus.
STAT1 min letti
Sharon Begley, Path-breaking Science Journalist Who Spun Words Into Gold, Dies At 64
From the glory days of print magazines to 2020’s Twitter-crazed news cycles, Sharon Begley won more awards and accolades than could fit in an obituary. The accomplishments she was prouder…